Company intelligence / Profile preview

Nora Pharma

Ownership: Private
Employees: ~42
Development stage: Commercial

Overview

Nora Pharma has 52 generic prescription drugs on the market in Canada and received approval for its first Biosimilar product in April 2024. The company plans to expand its offering to 60 generic prescription drugs by the end of 2024[3].

Therapeutic areas: Other
Modalities: Generic medicationsBiosimilars
Industry: Biotech

Drug pipeline

1 asset

NIOPEG

Commercial

Beyond the preview

Go deeper on Nora Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nora Pharma.

Explore the full profile